These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Long-term treatment of blepharospasm with botulinum toxin type A.
    Author: Nüssgens Z, Roggenkämper P.
    Journal: Ger J Ophthalmol; 1995 Nov; 4(6):363-7. PubMed ID: 8751102.
    Abstract:
    The treatment of essential blepharospasm with botulinum toxin has been known for a decade and is becoming increasingly more popular. To our knowledge, only a few longterm studies in major patient populations have been published. Of a total of more than 1,600 patients, results of treatment were evaluated in 115 patients (31 men and 84 women) treated continuously for a minimum of 3 years and a maximum of 8 years (mean, 5.7 years). Patients were divided into two groups. Group I represents the "good responders" and contains all patients who received only 4-10 injections over that time (n = 55). Group II represents the "poor responders, " who received at least 20 injections over that period (n = 60). Group I received a mean of 7.1 injections, whereas group II had a mean of 24.4 injections (total, 1,855). In group I the beneficial effect lasted for an average of 14.6 weeks (range, 2-52 weeks), whereas group II had a mean beneficial effect for only 6.8 weeks (range, 0-18 weeks). The time of efficacy remained statistically stable even in the case of frequent treatment (up to 36 injections in group II). Systemic or severe long-lasting local side effects were never observed; the most frequent side effects were: group I-ptosis, 5.4%; tearing, 5.1%; double vision, 1.8%; and lid lag, 1.5%; group II-ptosis, 4.3%; tearing, 3.3% lid lag, 1.9%, and double vision, 1.6%. The treatment of essential blepharospasm with botulinum toxin is a very effective therapy with minimal and transient complications. It may be used for long-term treatment without showing a decrease in efficacy.
    [Abstract] [Full Text] [Related] [New Search]